株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

デジタル定量吸入器の世界市場:2019年~2023年

Digital Dose Inhalers Market by Product and Geography - Global Forecast and Analysis 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 910206
出版日 ページ情報 英文 130 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
デジタル定量吸入器の世界市場:2019年~2023年 Digital Dose Inhalers Market by Product and Geography - Global Forecast and Analysis 2019-2023
出版日: 2019年08月30日 ページ情報: 英文 130 Pages
概要

世界のデジタル定量吸入器市場は、慢性呼吸器疾患の有病率の増加、有名企業による製品の発売の増加、技術進歩などが成長促進要因となり、予測期間中に約13%のCAGRで拡大する見込みです。ただし、デジタル定量吸入器に関連する高いコスト、認識不足と相互運用性の欠如、デジタル定量吸入器の限定的な入手可能性およびデジタルセキュリティの問題により、予測期間にわたってデジタル定量吸入器産業の成長が妨げられる可能性があります。

当レポートでは、世界のデジタル定量吸入器市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • 定量およびソフトミスト吸入器
  • 乾燥粉末吸入器
  • 市場機会:製品別

第7章 顧客情勢

第8章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • AIの高度な統合とIoTの採用
  • 事業戦略
  • インターネット接続の増加とスマートフォンデバイスの使用

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競争シナリオ

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Novartis AG
  • OPKO Health Inc.
  • Teva Pharmaceutical Industries Ltd.

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

目次
Product Code: IRTNTR31966

About this market

Technavio's digital dose inhalers market analysis considers sales from both metered-dose and soft mist inhalers and dry powder inhalers . Our analysis also considers the sales of digital dose inhalers in Asia. Europe, North America, and ROW. In 2018, the metered dose and soft mist inhalers segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as delivery of accurate dose during inhalation, cost-effectiveness will play a significant role in the metered-dose and soft mist inhalers segment to maintain its market position. Also, our global digital dose inhalers market report looks at factors such as increasing prevalence of chronic respiratory diseases, increasing product launches by prominent players, and technological advances. However, high costs associated with digital dose inhalers, lack of awareness and interoperability, and limited availability of digital dose inhalers and digital security issues may hamper the growth of the digital dose inhalers industry over the forecast period.

Overview

Technological advancements

Digital dose inhalers or smart inhalers are an advanced type of inhalers, which help to achieve an effective outcome for COPD and asthma. Pharmaceutical companies are developing smart mist inhalers that optimize and improve drug delivery in patients with COPD. Market vendors are increasingly integrating Bluetooth technology and digitalizing inhaler devices to minimize common errors by measuring patient inhalation, increase the drug delivery efficacy, reduce health care costs, improve medication adherence, and enhance patient outcome. Such benefits of technological advancements will lead to the expansion of the global digital dose inhalers market at a CAGR of almost 13% during the forecast period.

Rising integration of AI and the adoption of IoT

Digitalization has opened the doors for healthcare professionals to improve the treatment of asthma and COPD. AI technology uses algorithms and software to analyze complex medical data and minimizes the need for direct human input. Moreover, IoT based digital inhalers help customers to monitor their condition, understand the measurement of dosage, and prevent subsequent respiratory attacks. The sensors integrated digital dose inhaler systems help in minimizing emergency visits reducing risks and enhances patient outcome. This rise in the integration of AI and IoT is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global digital dose inhalers market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global digital dose inhalers market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading digital dose inhalers manufacturers, that include AstraZeneca Plc, GlaxoSmithKline Plc, Novartis AG, OPKO Health Inc., Teva Pharmaceutical Industries Ltd.

Also, the digital dose inhalers market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Metered dose and soft mist inhalers - Market size and forecast 2018-2023
  • Dry powder inhalers - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Rising integration of AI and adoption of IoT
  • Business strategies
  • Growing internet connectivity and use of smartphone devices

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Novartis AG
  • OPKO Health Inc.
  • Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global medical devices market
  • Exhibit 03: Segments of global medical devices market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Hospital admission rate for asthma and COPD in adults in 2015 per 100,000 population
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Product - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: Metered dose and soft mist inhalers - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Metered dose and soft mist inhalers - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Dry powder inhalers - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Dry powder inhalers - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by product
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Percentage of population with self-reported COPD aged 15 and over in 2014 (Europe)
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: AstraZeneca Plc - Vendor overview
  • Exhibit 47: AstraZeneca Plc - Product segments
  • Exhibit 48: AstraZeneca Plc - Organizational developments
  • Exhibit 49: AstraZeneca Plc - Geographic focus
  • Exhibit 50: AstraZeneca Plc - Segment focus
  • Exhibit 51: AstraZeneca Plc - Key offerings
  • Exhibit 52: AstraZeneca Plc - Key customers
  • Exhibit 53: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 54: GlaxoSmithKline Plc - Business segments
  • Exhibit 55: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 56: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 57: GlaxoSmithKline Plc - Segment focus
  • Exhibit 58: GlaxoSmithKline Plc - Key offerings
  • Exhibit 59: GlaxoSmithKline Plc - Key customers
  • Exhibit 60: Novartis AG - Vendor overview
  • Exhibit 61: Novartis AG - Business segments
  • Exhibit 62: Novartis AG - Organizational developments
  • Exhibit 63: Novartis AG - Geographic focus
  • Exhibit 64: Novartis AG - Segment focus
  • Exhibit 65: Novartis AG - Key offerings
  • Exhibit 66: Novartis AG - Key customers
  • Exhibit 67: OPKO Health Inc. - Vendor overview
  • Exhibit 68: OPKO Health Inc. - Business segments
  • Exhibit 69: OPKO Health Inc. - Organizational developments
  • Exhibit 70: OPKO Health Inc. - Geographic focus
  • Exhibit 71: OPKO Health Inc. - Key offerings
  • Exhibit 72: OPKO Health Inc. - Key customers
  • Exhibit 73: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 74: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 75: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 76: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 77: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 78: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 79: Validation techniques employed for market sizing
  • Exhibit 80: Definition of market positioning of vendors
Back to Top